251 related articles for article (PubMed ID: 38507188)
1. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
2. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
Deng S; Zhao H; Chai S; Sun Y; Shen P; Lin H; Zhan S
Front Endocrinol (Lausanne); 2024; 15():1369908. PubMed ID: 38803473
[TBL] [Abstract][Full Text] [Related]
3. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
Ahmad A; Sabbour H
Cardiovasc Diabetol; 2024 Mar; 23(1):99. PubMed ID: 38500154
[TBL] [Abstract][Full Text] [Related]
5. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
Bonora BM; Russo G; Leonetti F; Strazzabosco M; Nollino L; Aimaretti G; Giaccari A; Broglio F; Consoli A; Avogaro A; Fadini GP;
J Endocrinol Invest; 2024 Jun; 47(6):1395-1403. PubMed ID: 38369592
[TBL] [Abstract][Full Text] [Related]
8. Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues.
Battini V; Barbieri MA; Carnovale C; Spina E; Clementi E; Sessa M
J Neurol; 2024 Jun; 271(6):3417-3425. PubMed ID: 38517522
[TBL] [Abstract][Full Text] [Related]
9. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
Tran KL; Park YI; Pandya S; Muliyil NJ; Jensen BD; Huynh K; Nguyen QT
Am Health Drug Benefits; 2017 Jun; 10(4):178-188. PubMed ID: 28794822
[TBL] [Abstract][Full Text] [Related]
10. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
[TBL] [Abstract][Full Text] [Related]
11. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
Franchi M; Pellegrini G; Avogaro A; Buzzetti G; Candido R; Cavaliere A; Consoli A; Marzona I; Mennini FS; Palcic S; Corrao G
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38802266
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Courtney H; Nayar R; Rajeswaran C; Jandhyala R
Diabetes Metab Syndr Obes; 2017; 10():79-87. PubMed ID: 28331351
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
Dai M; Dai S; Gu L; Xiang Z; Xu A; Lu S; Yang Y; Zhou C
J Clin Res Pediatr Endocrinol; 2024 Jun; ():. PubMed ID: 38828884
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of novel glucose-lowering drugs.
Rathmann W; Bongaerts B
Diabetologia; 2021 Jun; 64(6):1201-1212. PubMed ID: 33594477
[TBL] [Abstract][Full Text] [Related]
16. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
Sivaraman SA; Sabareesh V
Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201
[TBL] [Abstract][Full Text] [Related]
17. Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
Rodriguez-Valadez JM; Tahsin M; Masharani U; Park M; Hunink MGM; Yeboah J; Li L; Weber E; Berkalieva A; Avezaat L; Max W; Fleischmann KE; Ferket BS
J Am Heart Assoc; 2024 Feb; 13(4):e032463. PubMed ID: 38362889
[TBL] [Abstract][Full Text] [Related]
18. Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials.
Wang A; Shi W; Zhang N; Tang H; Feng X
Clin Ther; 2024 May; ():. PubMed ID: 38796335
[TBL] [Abstract][Full Text] [Related]
19. Preventing CXCL12 elevation helps to reduce acute exacerbation of COPD in individuals co-existing type-2 diabetes: A bioinformatics and clinical pharmacology study.
Xue H; Chen Q; Lan X; Xu H; Yang H; Lin C; Xue Q; Xie B
Int Immunopharmacol; 2024 May; 132():111894. PubMed ID: 38569426
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).
Shao DW; Zhao LJ; Sun JF
Eur J Med Chem; 2024 Jun; 272():116464. PubMed ID: 38704940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
